Navigation Links
Mayo Genomic Discovery: Protecting Kidney Function During Heart Failure
Date:6/15/2009

ROCHESTER, Minn., June 15 /PRNewswire-USNewswire/ -- Mayo Clinic cardiology researchers have found a peptide that helps preserve and improve kidney function during heart failure, without affecting blood pressure. Earlier variations of this peptide caused blood pressure to drop limiting the potential benefits to the kidneys. The findings appear in the current Proceedings of the National Academy of Sciences.

"Heart failure itself and some of the approaches used to treat it can have detrimental effects on the kidneys," says Mayo cardiologist and lead researcher Robert Simari, M.D. "Our hope is that this compound will help protect kidney function while you're being treated, and possibly shorten your hospital stay and keep you out of the hospital."

This new peptide (a unique link of amino acids) has been tested in the laboratory and in animal models and is expected to move into clinical trials next year.

"One of the biggest additional concerns for patients with heart failure is the health of their kidneys," says Dr. Simari. "The extreme case is that it can lead to the kidneys shutting down completely." Nearly 5 million Americans are living with heart failure, a condition where the heart can't pump enough blood to meet the body's needs. Symptoms include shortness of breath, exercise intolerance and fluid retention. All can occur when heart function is impaired.

Seven Years of Research

The mapping of the human genome (2000-2003) revealed a gene that produces a protein called BNP (B-type natriuretic peptide). BNP was not only useful in diagnosing heart problems, it also proved therapeutic in treating heart failure. Unfortunately, says Dr. Simari, it had limited use because many heart failure patients experience low blood pressure and BNP lowered it further.

The Mayo investigators discovered an alternative splicing (AS) of BNP in messenger RNA (produced by the same gene). When they shortened the amino acid sequence of ASBNP for testing, they found that it had the same therapeutic benefits as BNP, but without the side effects to blood pressure. Positive impacts include increasing the kidney filtration rate, suppressing harmful protein production, and keeping water and salt flowing from the body. Potentially, this new drug would be given by IV to patients who are being treated in the hospital.

"There's an important reduction of kidney function every time one of these acute heart failure episodes happens," says Dr. Simari. "And by stopping one or more of those decrements, we hope there will be an overall improvement in long-term maintenance of kidney function."

Others on the team include Shuchong Pan, M.D., Ph.D.; Horng Chen, M.D.; Guido Boerrigter, M.D.; Candace Lee; Laurel Kleppe; Amir Lerman, M.D.; Margaret Redfield, M.D.; John Burnett, Jr., M.D.; all from Mayo Clinic, and Deborah Dickey, Ph.D.; Jennifer Hall, Ph.D.; and Lincoln Potter, Ph.D., all from the University of Minnesota. The research was funded by Mayo Clinic, the National Institutes of Health, and Anexon, Inc.

Mayo Clinic and five of the investigators associated with this research have a financial interest in the technology studied in the research. In accordance with the Bayh-Dole Act, that technology has been licensed to Anexon. Mayo Clinic and Drs. R. Simari and Dr. S. Pan have received royalties from the licensing of that technology of greater than the federal threshold for significant financial interest. Drs. J. Burnett, M. Redfield and H. Chen have received royalties less than the federal threshold for significant financial interest. In addition, Mayo Clinic holds an equity position in Anexon.

About Mayo Clinic

Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. Doctors from every medical specialty work together to care for patients, joined by common systems and a philosophy of "the needs of the patient come first." More than 3,300 physicians, scientists and researchers and 46,000 allied health staff work at Mayo Clinic, which has sites in Rochester, Minn., Jacksonville, Fla., and Scottsdale/Phoenix, Ariz. Collectively, the three locations treat more than half a million people each year. To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. For information about research and education visit www.mayo.edu. MayoClinic.com (www.mayoclinic.com) is available as a resource for your health stories.

VIDEO ALERT: Additional audio and video resources, including excerpts from an interview with Dr. Simari describing the research, are available on the Mayo Clinic News Blog.


'/>"/>
SOURCE Mayo Clinic
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Microarray provides 3 genomic guides to breast cancer treatment decisions
3. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
4. Genomic Health to Present at ThinkEquity Partners Fifth Annual Growth Conference
5. Genomic profiling of lung tumors helps doctors choose most effective treatment
6. Genomic technologies to identify toxic chemicals should be developed
7. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
8. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
9. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test:
10. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
11. Genomic Health to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... ... Family Dermatology has recently joined their multi-specialty medical group. The dermatology practice ... cosmetic services. , “We’re excited to add this excellent dermatology practice to our ...
(Date:1/20/2017)... ... ... A new partnership between Goodwill® and Roadie, Inc. aims to make it easier ... couches to dressers and bicycles. Roadie — the national on-the-way delivery network — will ... through February 28th. , “January is an exciting time when resolutions are made ...
(Date:1/20/2017)... ... January 20, 2017 , ... Lice Troopers, the lice removal company based ... school-aged children since the holiday season. , “It happens every year around this ... hugs and taking photos, which is the head-to-head gateway that lice need to spread.” ...
(Date:1/20/2017)... ... 20, 2017 , ... Vitamin Well has launched two new ... have been produced in collaboration with Zlatan Ibrahimovic and have been developed to ... a successful launch in Sweden last year, the next generation sports drinks VW+001 ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... ... vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in a study ... Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive Expiratory Pressure ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... -- Report Details What can be expected ... to grow at the fastest rates? This visiongain report ... opportunities and prospects. Our 190-page report provides 124 ... in the industry and the future market prospects. Our ... all the major categories of the ophthalmic devices market. ...
(Date:1/19/2017)... 19, 2017 This report on the opioid ... scenario of the global market. Large number of chronic ... chronic constipation is a major side effect of consumption ... novel targeted therapy has been prescribed to treat opioid ... targeted medicines, and growing awareness about the therapy are ...
(Date:1/19/2017)... 2017 Accuray Incorporated (Nasdaq: ARAY ... continue to set the bar for excellence in customer ... user satisfaction rating among radiation treatment delivery systems in ... Market Intelligence Briefing™. The most recent ratings trend also ... industry peers for 11 of the past 12 quarters. ...
Breaking Medicine Technology: